

Special Issue

Advances in Treatment of Rare Tumors

Message from the Guest Editors

Gestational trophoblastic disease (GTD) is a rare entity comprising several pregnancy-related tumor subtypes, ranging from premalignant to malignant disease (commonly referred to as “gestational trophoblastic neoplasia”, GTN). Given its rarity, management and treatment can be difficult. Since the introduction of platinum-based chemotherapy, the prognosis of patients affected by GTN has dramatically improved. However, chemotherapy-resistant disease still represents a major challenge. In recent years, new, promising strategies in treatment have emerged. The aim of this Special Issue is to give an updated insight into this topic, with a particular focus on future perspectives for the treatment of GTN.

Guest Editors

Prof. Dr. Giorgia Mangili

Department of Gynaecological Oncology, San Raffaele Scientific Institute, 20132 Milan, Italy

Dr. Alice Bergamini

Department of Obstetrics and Gynecology, Ospedale San Raffaele, 20132 Milan, Italy

Deadline for manuscript submissions

closed (20 September 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/68725

Cancers

Editorial Office

MDPI, Grosspeteranlage 5

4052 Basel, Switzerland

Tel: +41 61 683 77 34

cancers@mdpi.com

mdpi.com/journal/

cancers





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)